Many patients with psychiatric disorders do not obtain remission from available pharmacological and psychotherapeutic treatments. Recent studies have demonstrated that there is a role for the rational use of ‘combination therapy’ when treating patients with serious and treatment-resistant mental illnesses. When prescribing multiple medications, it is easy, however, to fall into irrational polypharmacy. We present a framework that clinicians can use to avoid the pitfall of irrational polypharmacy. When using combination therapy, clinicians should consider: (a) pharmadynamic redundancy; (b) pharmacodynamic interactions; (c) pharmacokinetic interactions; and (d) avoid inadequate dosing of medications. Clinicians should also (e) regularly reassess the need for and benefit of continued combination therapy.
AnderssonMLBjorkhem-BergmanLLindhJD (2011) Possible drug-drug interaction between quetiapine and lamotrigine–evidence from a Swedish TDM database. Br J Clin Pharmacol72: 153–156.
BauerMAdliMBschorT. (2010) Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology62: 36–42.
4.
BaumannPHiemkeCUlrichS. (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry37: 243–265.
5.
BlierP (2012) Combined treatments for depression as for other medical disorders. Am J Psychiatry169: 95–96.
6.
BlierPBlondeauC (2011) Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord128 (Suppl 1): S3–S10.
7.
BlierPGobbiGTurcotteJE. (2009) Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol19: 457–465.
8.
BlierPWardHETremblayP. (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry167: 281–288.
9.
BowdenCLVietaEIceKS. (2010) Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry71: 130–137.
10.
CastbergISkogvollESpigsetO (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry68: 1540–1545.
11.
ChernolozOEl MansariMBlierP (2012) Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Neuropsychopharmacology
12.
CorrellCURummel-KlugeCCorvesC. (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bulletin35: 443–457.
13.
DarwishMBondMHellriegelET. (2011) Investigation of a Possible Interaction Between Quetiapine and Armodafinil in Patients With Schizophrenia: An Open-Label, Multiple-Dose Study. J Clin Pharmacol. Epub ahead of print8September2011. DOI: 10.1177/009127001141457210.1177/0091270011414572.
14.
DawsonLAWatsonJM (2009) Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS neuroscience & therapeutics15: 107–117.
15.
EssockSMSchoolerNRStroupTS. (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry168: 702–708.
16.
FernandezJAlonsoJMAndresJI. (2005) Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem48: 1709–1712.
17.
FindlingRLShortEJMcNamaraNK. (2007) Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry46: 1445–1453.
18.
GeddesJRGoodwinGMRendellJ. (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet375: 385–395.
19.
GhanbariREl MansariMShahidM. (2009) Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol19: 177–187.
20.
GlickIDPhamDDavisJM (2006) Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry67: 1261–1265.
21.
GoffDCDixonL (2011) Antipsychotic polypharmacy: are two ever better than one?Am J Psychiatry168: 667–669.
22.
HoracekJBubenikova-ValesovaVKopecekM. (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS drugs20: 389–409.
23.
IpserJCCareyPDhansayY. (2006) Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane database of systematic reviews: CD005473.
24.
JensenNHRodriguizRMCaronMG. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology33: 2303–2312.
25.
KingsburySJLotitoML (2007) Psychiatric polypharmacy: the good, the bad, and the ugly. Psychiatric Times24 (4): NP.
26.
KingsburySJYiDSimpsonGM (2001) Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv52: 1033–1036.
27.
KronenbergerWGGiauqueALLafataDE. (2007) Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry17: 334–347.
28.
LevyFHobbesG (1996) Does haloperidol block methylphenidate? Motivation or attention?Psychopharmacology126: 70–74.
29.
LiebermanJAStroupTSMcEvoyJP. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med353: 1209–1223.
30.
MarcusRKhanARollinL. (2011) Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar disorders13: 133–144.
31.
McEvoyJPLiebermanJAStroupTS. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry163: 600–610.
32.
MeyerJHWilsonAASagratiS. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry161: 826–835.
33.
MojtabaiROlfsonM (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry67: 26–36.
34.
NelsonJCPapakostasGI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry166: 980–991.
35.
NemeroffCBEvansDLGyulaiL. (2001) Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry158: 906–912.
36.
Newman-TancrediAGavaudanSConteC. (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol355: 245–256.
37.
NorrisSBlierP (2009) Duloxetine and Milnacipran. In: SchatzbergAFNemeroffCB (eds) The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed.Washington, D.C.: American Psychiatric Pub., 454–455.
38.
PerlisRHOstacherMJPatelJK. (2006) Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry163: 217–224.
39.
PreskornSHFlockhartD (2009) 2010 Guide to psychiatric drug interactions. Prim Psychiatry16: 45–74.
RazACampbellNGuindiD. (2011) Placebos in clinical practice: comparing attitudes, beliefs, and patterns of use between academic psychiatrists and nonpsychiatrists. Can J Psychiatry56: 198–208.
42.
RushAJTrivediMHStewartJW. (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry168: 689–701.
43.
RushAJTrivediMHWisniewskiSR. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry163: 1905–1917.
44.
SchefferREKowatchRACarmodyT. (2005) Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry162: 58–64.
45.
TakanoASuzukiKKosakaJ. (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology185: 395–399.
46.
van der LoosMLMulderPGHartongEG. (2009) Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry70: 223–231.
47.
WeizmanAWeitzRSzekelyGA. (1984) Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry23: 295–298.
48.
YanofskiJ (2010) The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry7: 18–23.
49.
ZeniCPTramontinaSKetzerCR. (2009) Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Am Acad Child Adolesc Psychiatry19: 553–561.
50.
ZimmermanMMattiaJIPosternakMA (2002) Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?Am J Psychiatry159: 469–473.
